Which mechanism best describes how colchicine relieves acute gout inflammation?
Choose an answer, then check it.
Clinical Pharmacology · Anti-Inflammatory and Immunosuppressive Medications
Gout Medications
On this page 6 sections
In 30 seconds
Gout is joint inflammation from urate crystals depositing in and around joints, and gout pharmacology splits cleanly into two jobs that must never be confused: putting out the fire of an acute flare, and lowering the body's urate load so future fires don't start. Acute-flare drugs — NSAIDs, corticosteroids, colchicine, anakinra — calm inflammation but do nothing to urate levels. Urate-lowering therapy (ULT) — allopurinol, febuxostat, probenecid, pegloticase — reduces urate over time but does not relieve pain today and can even provoke a flare if started carelessly. Mixing up these two goals, or reflexively stopping or starting ULT during an attack, is the classic student and clinical error.
The college version
Acute Flare Treatment
An acute gout flare is intense joint inflammation triggered by the immune system reacting to urate crystals as if they were foreign invaders. Treatment goals are rapid pain and inflammation control, not urate reduction. First-line options are NSAIDs (at anti-inflammatory intensity) and corticosteroids, either oral/systemic or injected directly into the joint (intra-articular) when one or two joints are involved, avoiding systemic steroid exposure. Colchicine is a distinctive option: it binds tubulin, disrupting microtubule assembly, which impairs neutrophil chemotaxis, migration, and activation — neutrophils are the cells driving the crystal-induced inflammatory cascade. Colchicine has a narrow therapeutic margin: gastrointestinal upset, especially severe diarrhea, is the classic dose-limiting toxicity signaling the drug should be reduced or stopped. It requires dose adjustment or avoidance in significant renal or hepatic impairment, and it is dangerously affected by inhibitors of CYP3A4 and P-glycoprotein (its major clearance pathways) — drugs like clarithromycin can raise colchicine levels into a toxic, sometimes fatal range, and combining colchicine with statins raises the risk of myopathy/rhabdomyolysis. For flares refractory to these options, or when NSAIDs/steroids/colchicine are contraindicated, anakinra (an IL-1 receptor antagonist) targets the IL-1-driven inflammatory pathway directly and is reserved for difficult cases.
Urate-Lowering Therapy
ULT addresses the underlying problem: chronic hyperuricemia that allows crystals to form. Xanthine oxidase inhibitors — allopurinol and febuxostat — block the enzyme that produces uric acid, working regardless of whether the patient overproduces or underexcretes urate. Allopurinol carries a risk of a severe hypersensitivity syndrome (fever, rash, organ involvement) that is strongly associated with the HLA-B*5801 allele, more common in certain Southeast Asian and other specific ancestral populations, prompting genetic screening in some patients before starting therapy. Allopurinol also interacts dangerously with azathioprine and mercaptopurine: since xanthine oxidase normally helps metabolize these agents, inhibiting it can cause their levels to accumulate, producing severe, potentially fatal bone marrow suppression. Febuxostat is an alternative xanthine oxidase inhibitor but carries a cardiovascular safety signal, warranting caution, particularly in patients with existing cardiovascular disease. Probenecid works differently: it is a uricosuric that blocks urate reabsorption in the renal tubule, increasing urinary excretion. It requires adequate kidney function to work and adequate hydration to reduce the risk of uric acid stone formation, and it is inappropriate for patients who overproduce urate or who already form kidney stones, since pushing more urate through the urine worsens stone risk. Pegloticase, a recombinant uricase enzyme given by infusion, converts uric acid into a more soluble compound and is reserved for severe, refractory tophaceous gout unresponsive to other therapies.
The Two Golden Rules
First, initiating or changing the dose of any ULT can itself trigger an acute flare, because shifting urate levels destabilizes existing crystal deposits; anti-inflammatory prophylaxis (typically low-dose colchicine or an NSAID) is co-prescribed for a period around ULT initiation to blunt this risk. Second, ULT is traditionally not started during an acute attack (it won't help the pain and may worsen it) and is not reflexively stopped either — a patient already stable on ULT continues it uninterrupted through a flare, while flare treatment is layered on top.
Lifestyle and Contributing Drugs
Alcohol, purine-rich foods, obesity, and dehydration all raise flare risk. Certain medications also elevate urate and should be reviewed: thiazide diuretics and low-dose aspirin both reduce renal urate excretion and can aggravate hyperuricemia.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine tiny sharp sand crystals building up in a joint, like sugar crystallizing in a jar. When your body notices the crystals, it panics and causes a painful, swollen attack — that's a gout flare. Some medicines are like a fire extinguisher: they put out today's fire fast (NSAIDs, steroids, colchicine, and for tough cases anakinra), but they don't touch the sugar jar itself. Other medicines are like slowly pouring out the extra sugar so the jar never overflows again (allopurinol, febuxostat, probenecid, pegloticase) — but they work over weeks and months, not today, and stirring the jar while pouring can actually kick loose crystals and start a new fire. So the rule is: fight today's fire with fire-extinguisher drugs, and manage the sugar jar separately and steadily, never confusing the two jobs.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient on chronic azathioprine for an autoimmune condition is newly prescribed allopurinol for gout. What serious interaction should the prescriber anticipate, and why does it occur?
Show answer
Severe, potentially fatal bone marrow suppression.
Allopurinol blocks the xanthine oxidase enzyme that normally helps break down azathioprine's active metabolites, so those metabolites build up to toxic levels and suppress the bone marrow dangerously; the combination generally requires major dose reduction or avoiding allopurinol.
Explain why anti-inflammatory prophylaxis is typically added when a patient first starts urate-lowering therapy, even though that therapy is meant to prevent flares long-term.
Show answer
Because starting or changing urate-lowering therapy can itself trigger a flare.
Lowering urate destabilizes crystals already sitting in joints, so a short course of an anti-inflammatory like colchicine or an NSAID is added at initiation to cover that vulnerable window while the long-term urate-lowering effect takes hold.
Quick check
3 questions here. Answers stay hidden until you check.
A patient stable on allopurinol for years is admitted with an acute gout flare. What is the most appropriate action regarding allopurinol?
Choose an answer, then check it.
Which patient would be a poor candidate for probenecid?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.